- Location
Theravance
"-
FDA Has Approved GSK and Theravance's Anoro Ellipta
Dec 20, 2013The US Food and Drug Administration (FDA) has approved GlaxoSmithKline (GSK) and Theravance's Anoro Ellipta as a once-daily, long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease ...
-
GSK Have Received Marketing Authorization From The European Commission for Relvar Ellipta
Nov 20, 2013GlaxoSmithKline (GSK) and Theravance have received marketing authorization from the European Commission (EC) for their jointly-developed asthma and chronic obstructive pulmonary disease (COPD) drug 'Relvar Ellipta'. Relvar, which is a ...
Tags: GSK, Relvar Ellipta
-
GSK and Theravance Reaveals The Availability of Breo Ellipta
Nov 4, 2013UK-based GlaxoSmithKline (GSK) and US-based Theravance have announced the availability of BREO ELLIPTA, a once-daily prescription medicine for chronic obstructive pulmonary disease (COPD), in the US pharmacies. BREO ELLIPTA is a ...
-
Theravance Announced That The EMA Has Recommended Marketing Approval
Sep 20, 2013GlaxoSmithKline and biopharmaceutical company Theravance have announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing approval for fluticasone furoate/vilanterol ...
-
FDA Has Recommended The Approval of Investigational Copd Drug in US
Sep 13, 2013The Pulmonary-Allergy Drugs Advisory Committee (PADAC) of the US Food and Drug Administration (FDA) has recommended the approval of GlaxoSmithKline (GSK) and Theravance's umeclidinium/vilanterol as a treatment for chronic obstructive ...
Tags: Health, Medicine, Investigational Copd Drug
-
GSK and Theravance Have Withdrawn License Application for FF and VI
Jul 16, 2013GlaxoSmithKline (GSK) and Theravance have withdrawn license application for the use of inhaled drug fluticasone furoate (FF) and vilanterol (VI), with proposed brand name of Relvar Ellipta, as treatment for chronic obstructive pulmonary ...
Tags: Japan, GSK, Relvar License
-
The US Food and Drug Administration Has Cleared Theravance's Vibativ
Jun 25, 2013The US Food and Drug Administration (FDA) has cleared Theravance's Vibativ (telavancin) for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP). With a dual mechanism of action, the bactericidal, ...
Tags: Health&Medicine, FDA, US
-
BREO ELLIPTA Will Help Patients Breathe Better Day-to-Day
May 14, 2013GlaxoSmithKline (GSK) and Theravance have announced the FDA approval of Breo Ellipta as maintenance treatment of airflow obstruction in chronic obstructive pulmonary disease (COPD) patients. The inhaled long-term, once-daily maintenance ...
Tags: GSK, Theravance, Copd Therapy
-
GSK and Theravance Have Announced The Submission of a Regulatory Application in Japan
Apr 26, 2013GSK and Theravance have announced the submission of a regulatory application for Anoro Ellipta (UMEC/VI) (62.5/25mcg and 125/25mcg doses) in Japan. UMEC/VI combines a long-acting muscarinic antagonist (LAMA) GSK573719 or umeclidinium ...
-
Clinigen Has Acquired Cardioxane (Dexrazoxane) From Novartis for $33m
Apr 6, 2013Clinigen has acquired Cardioxane (dexrazoxane) from Novartis for $33m, which is payable in two tranches. As per the agreement, Clinigen will manufacture, register, distribute, and commercialize the product in countries where current ...
Tags: Clinigen, Cardioxane, Medicine
-
Clinigen Group and Theravance Have Signed an Exclusive Commercialization Agreement
Mar 13, 2013Clinigen Group and Theravance have signed an exclusive commercialization agreement for Vibativ (telavancin) in the EU and few other countries located in Europe. The bactericidal, once-daily injectable lipoglycopeptide antibacterial agent ...
-
GlaxoSmithKline and Theravance Have Announced The MAA Submission for Anoro
Jan 11, 2013GlaxoSmithKline and Theravance have announced the MAA submission for Anoro in Europe for patients with chronic obstructive pulmonary disease (COPD). The COPD therapy, administered using the ELLIPTA inhaler, is a combination of GSK573719 ...
Tags: GlaxoSmithKline, COPD therapy, chronic obstructive pulmonary disease
-
GSK and Theravance Have Submitted a Regulatory Application in The US
Dec 20, 2012GlaxoSmithKline (GSK) and Theravance have submitted a regulatory application in the US for the investigational once-daily LAMA/LABA combination medicine, umeclidinium bromide (UMEC/VI), to treat chronic obstructive pulmonary disease (COPD) ...
Tags: GlaxoSmithKline, regulatory application, Medicine, FDA
-
Theravance Has Commenced Phase 2b Study Desined to Evaluate Varying Doses of TD-4208
Dec 14, 2012Theravance has commenced Phase 2b study desined to evaluate varying doses of TD-4208 in patients with moderate to severe chronic obstructive pulmonary disease (COPD). Theravance leveraged its multivalent approach of drug design to ...
Tags: drug, long-acting medicines, long-acting muscarinic antagonist
-
Theravance Has Entered Into a Research Partnership with Merck
Nov 28, 2012Theravance has entered into a research partnership with Merck, known as MSD outside the US and Canada, for the development of potential cardiovascular therapeutics to treat hypertension and heart failure. As per the agreement, Merck will ...
Tags: Cardiovascular Therapeutics, Theravance, Merck, MSD